Compare PCRX & MQY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCRX | MQY |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 839.0M |
| IPO Year | 2011 | N/A |
| Metric | PCRX | MQY |
|---|---|---|
| Price | $20.56 | $11.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $35.33 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 184.8K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.73% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $716,791,000.00 | N/A |
| Revenue This Year | $6.21 | N/A |
| Revenue Next Year | $8.26 | N/A |
| P/E Ratio | $43.50 | ★ N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $18.80 | $9.82 |
| 52 Week High | $27.64 | $12.52 |
| Indicator | PCRX | MQY |
|---|---|---|
| Relative Strength Index (RSI) | 36.14 | 41.32 |
| Support Level | $18.80 | $11.28 |
| Resistance Level | $21.12 | $11.28 |
| Average True Range (ATR) | 1.25 | 0.09 |
| MACD | -0.33 | -0.02 |
| Stochastic Oscillator | 22.98 | 6.58 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.